Astrid Bergbreiter1, Teresa Jaeger1, Antje Karle2, Diane Bitzinger2, Tobias Ettl3, Gerrit Spanier3, Herbert Jägle4, Reiner Neu5, Yorick Söder6, Matthias Evert7, Torsten E Reichert3, Mark Berneburg1, Christoph Brochhausen7, Julia Schreml8, Manfred Fliegauf9, Ulrich Salzer9, Andreas Redel10, Stephan Schreml11. 1. Department of Dermatology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 2. Department of Anaesthesiology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 3. Department of Maxillofacial Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 4. Department of Ophthalmology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 5. Department of Cardiothoracic Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 6. Department of Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 7. Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 8. Institute of Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany. 9. Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacherstr. 115, 79106, Freiburg, Germany. 10. Department of Anaesthesiology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany; Department of Anaesthesiology, St. Marien Hospital Amberg, Mariahilfbergweg 7, 92224, Amberg, Germany. 11. Department of Dermatology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. Electronic address: stephan@schreml.de.
Abstract
BACKGROUND: Mutations in NFKB1(nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) are associated with a variety of clinical symptoms, including lymphadenopathy, splenomegaly, hepatomegaly, autoimmune haemolytic anaemia, arthralgia, recurrent respiratory tract infections and post-operative necrotizing cellulitis. CASE PRESENTATION: We describe a case of a 47-year-old man, who presented with deep necrotizing cellulitis after incision of a submucous abscess by a dentist. Surgical intervention led to a massive progress. Pyoderma gangraenosum (PG) was diagnosed clinically and confirmed histopathologically. High dose corticosteroids and intravenous immunoglobulins (IVIG) improved wound healing dramatically. Until now, immune mediated inflammation events not only affected the skin, but also multiple inner organs, i.e. the heart, lungs and gut. Sequencing of all coding exons of NFKB1 revealed a heterozygous 1bp deletion in exon 23 predicting a frameshift starting at codon Ala891 and resulting in a subsequent stop codon at position 6 in the new reading frame: NM_003998.4: c.2671del; p.(Ala891Glnfs*6) Acute episodes were always successfully treated with corticosteroids, IVIG and concomitant antibiotics. To prevent further exacerbations, the patient receives IVIG once a month, low-dose corticosteroids and methotrexate. CONCLUSION: This is the first case of a patient with recurrent necrotizing cellulitis and immune mediated multi-organ involvement (heart, lungs, intestine) carrying the novel frameshift mutation c.2671del (p.Ala891Glnfs*6) in NFKB1 effectively treated with IVIG, low-dose corticosteroids and methotrexate.
BACKGROUND: Mutations in NFKB1(nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) are associated with a variety of clinical symptoms, including lymphadenopathy, splenomegaly, hepatomegaly, autoimmune haemolytic anaemia, arthralgia, recurrent respiratory tract infections and post-operative necrotizing cellulitis. CASE PRESENTATION: We describe a case of a 47-year-old man, who presented with deep necrotizing cellulitis after incision of a submucous abscess by a dentist. Surgical intervention led to a massive progress. Pyoderma gangraenosum (PG) was diagnosed clinically and confirmed histopathologically. High dose corticosteroids and intravenous immunoglobulins (IVIG) improved wound healing dramatically. Until now, immune mediated inflammation events not only affected the skin, but also multiple inner organs, i.e. the heart, lungs and gut. Sequencing of all coding exons of NFKB1 revealed a heterozygous 1bp deletion in exon 23 predicting a frameshift starting at codon Ala891 and resulting in a subsequent stop codon at position 6 in the new reading frame: NM_003998.4: c.2671del; p.(Ala891Glnfs*6) Acute episodes were always successfully treated with corticosteroids, IVIG and concomitant antibiotics. To prevent further exacerbations, the patient receives IVIG once a month, low-dose corticosteroids and methotrexate. CONCLUSION: This is the first case of a patient with recurrent necrotizing cellulitis and immune mediated multi-organ involvement (heart, lungs, intestine) carrying the novel frameshift mutation c.2671del (p.Ala891Glnfs*6) in NFKB1 effectively treated with IVIG, low-dose corticosteroids and methotrexate.
Authors: Diem-Tran I Nguyen; Amanda Grimes; Donald Mahoney; Sebastian Faro; William T Shearer; Aaron L Miller; Nicholas L Rider Journal: Front Pediatr Date: 2021-07-07 Impact factor: 3.418
Authors: Jessica Rojas-Restrepo; Andrés Caballero-Oteyza; Katrin Huebscher; Hanna Haberstroh; Manfred Fliegauf; Baerbel Keller; Robin Kobbe; Klaus Warnatz; Stephan Ehl; Michele Proietti; Bodo Grimbacher Journal: Front Immunol Date: 2021-12-17 Impact factor: 7.561
Authors: Manfred Fliegauf; Matias Kinnunen; Sara Posadas-Cantera; Nadezhda Camacho-Ordonez; Hassan Abolhassani; Laia Alsina; Faranaz Atschekzei; Delfien J Bogaert; Siobhan O Burns; Joseph A Church; Gregor Dückers; Alexandra F Freeman; Lennart Hammarström; Leif Gunnar Hanitsch; Tessa Kerre; Robin Kobbe; Svetlana O Sharapova; Kathrin Siepermann; Carsten Speckmann; Sophie Steiner; Nisha Verma; Jolan E Walter; Emma Westermann-Clark; Sigune Goldacker; Klaus Warnatz; Markku Varjosalo; Bodo Grimbacher Journal: Front Immunol Date: 2022-08-29 Impact factor: 8.786